Drug Trial Radar · NCT00566982
A Clinical Study to Evaluate the Safety of Ospemifene
Last checked: Nov 20, 2026Latest source record: May 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
426
Actual
Start
Oct 2007
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- Collaborators
- Hormos Medical; QuatRx Pharmaceuticals
- First posted
- Dec 4, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.
Conditions
- Atrophy
- Vaginal Diseases
Interventions
Ospemifene 60 mgDrug
60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
PlaceboDrug
Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal SmearTime frame: 12 weeks
- Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of Vaginal SmearTime frame: 12 weeks
- Mean Change From Baseline in Vaginal pHTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.